Outlook Therapeutics Inc. (NASDAQ: OTLK) announced it has commenced a best-efforts public offering of common stock and accompanying warrants. The biopharmaceutical company said the offering is subject to market conditions and there is no assurance regarding completion, timing, size or final terms.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. The company intends to use net proceeds primarily for working capital and general corporate purposes.

The securities are being offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission on March 28, 2024, and became effective on April 5, 2024. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC.

Outlook Therapeutics focuses on developing treatments for retina diseases using bevacizumab. The company's product LYTENAVA has received European Commission and MHRA marketing authorization for treating wet age-related macular degeneration and has been launched commercially in Germany, Austria, and the United Kingdom.

In the United States, the company's ONS-5010/LYTENAVA product remains investigational and under regulatory review.